公司资料
SELLAS Life Sciences Group, Inc. 股价、新闻与催化剂
- 股票代码:
- SLS
- 交易所:
- NASDAQ
- 行业:
- Life Science Tools
- 所在地:
- United States
股票表现
13.00 USD (+1.72%)
收盘价
最后更新: 2026年8月17日
1.55B USD
市值
股价为何变动
As of Aug 17, 2026, SLS closed up 1.72% at $13.00. No new same-company headline was identified in the current news window.
公司概览
Late-Stage Oncology Company
SELLAS Life Sciences develops therapies for hematologic malignancies and solid tumors. Its pipeline combines a WT1-targeted immunotherapy with a differentiated small-molecule CDK9 inhibitor.
Galinpepimut-S
Galinpepimut-S, or GPS, is a WT1-targeting immunotherapy licensed from Memorial Sloan Kettering Cancer Center. WT1 is expressed across multiple blood cancers and solid tumors, creating potential for both monotherapy and combination development.
REGAL Phase 3 Program
The Phase 3 REGAL trial evaluates GPS as maintenance therapy in acute myeloid leukemia patients who achieved complete remission after second-line salvage treatment. The event-driven study will proceed to final analysis after the prespecified 80th event.
SLS009
SLS009, also known as tambiciclib, is a selective CDK9 inhibitor designed to combine antitumor potency with reduced toxicity. SELLAS is evaluating the candidate in newly diagnosed frontline AML and preparing for potential clinical development in pancreatic cancer.
未来催化剂
- The prespecified 80th event in the Phase 3 REGAL study, triggering database lock, final analysis, and subsequent topline results.
- Topline data from the Phase 2 study of SLS009 in newly diagnosed frontline AML in the fourth quarter of 2026.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。